Phase II data for ALX Oncology’s evorpacept in gastric cancer raises the possibility that the company can succeed in an immunotherapy field that even some large drug companies have exited due to results that did not meet expectations.
The company presented data on 23 January at the American Society of Clinical Oncology Oncology’s Gastrointestinal Cancers Symposium from the...